Pain Management

  • Recofol
  • Sufentanil
  • Ruituoxi
  • AF102
  • Gastroenterology

  • Lactéol Fort
  • Oral Rehydration Salts
  • Nephrology

  • Phosmin
  • FC818
  • Luolinping
  • Calcitriol
  • M8
  • NKF201
  • NKF202
  • Oncology

  • 801
  • AD1
  • Consumer Health

  • Xiexinshu SR
  • High-C
  • C+
  • 801

    Product: 801 injection
    Indication: Treatment for various cancers (Rx)
    Status: Discovery

    801 is a novel podophyllotoxin and camptothecin combination that preserves the anti-tumor properties of both compounds, while reducing toxicity and drug resistance.

    Podophyllotoxin and camptothecin

    As related to tumor physiology, topoisomerase I and II repair strand breaks after DNA replication, and are found in higher concentrations in cancer cells than in normal cells. HIF-1α and VEGF are involved in tumor metastasis.

    Podophyllotoxin is currently prescribed to inhibit topoisomerase II, while camptothecin is prescribed to inhibit topoisomerase I, HIF-1α, and VEGF.

    However, both podophyllotoxin and camptothecin have relatively high toxicity profiles, and therefore can only be used in alternation. Such alternating treatment involving inhibition of either topoisomerase I or II builds drug resistance in many cancer patients over time.


    801 combines podophyllotoxin and camptothecin, inhibiting both topoisomerase I and II concurrently. Early studies indicate that the compound has nearly no toxicity against normal cells, which would enable more aggressive treatment with less risk of drug resistance.

        PUMC Pharmaceutical Co., Ltd.